ReviewFrontiers in immunology2024
Leprosy: treatment, prevention, immune response and gene function.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- miR-889-3p targets SLC35E1 in leprosy: Implications for therapeutic monitoring.PLoS neglected tropical diseases · 2026Article
- Article
- Relapsed Type II Lepromatous Reaction With Drug-Induced Hemolysis: A Case Report Highlighting Therapeutic Challenges.Cureus · 2026Article
- Leprosy elimination: are we winning the fight or losing focus?Annals of medicine · 2025Article
- Four-channel carbon dot fluorescent sensor array with a pattern recognition approach for the discrimination and quantification of rifamycin antibiotics.Mikrochimica acta · 2025Article
- Global disease and economic burden of main mycobacterial infections in the working-age population from 1990 to 2021 with a forecast to 2045.Infectious medicine · 2025Article
- Public health surveillance of tropical diseases in Madagascar: a scoping review of population burden, intervention strategies, and health system responses.BMC public health · 2025Article
- The Role ofInternational journal of molecular sciences · 2025Review
- Unraveling Drug Resistance inInternational journal of microbiology · 2025Review
- Revealing Erythema Nodosum Leprosum in a Leprosy Patient: A Case of Treatment Noncompliance.Case reports in infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the leprosy cases have fallen dramatically, the incidence of leprosy has remained stable over the past years, indicating that multidrug therapy seems unable to eradicate leprosy. More seriously, the emergence of rifampicin-resistant strains also affects the effectiveness of treatment. Immunoprophylaxis was mainly carried out through vaccination with the BCG but also included vaccines such as LepVax and MiP. Meanwhile, it is well known that the infection and pathogenesis largely depend on the host's genetic background and immunity, with the onset of the disease being genetically regulated. The immune process heavily influences the clinical course of the disease. However, the impact of immune processes and genetic regulation of leprosy on pathogenesis and immunological levels is largely unknown. Therefore, we summarize the latest research progress in leprosy treatment, prevention, immunity and gene function. The comprehensive research in these areas will help elucidate the pathogenesis of leprosy and provide a basis for developing leprosy elimination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.